I follow quite a lot of companies -- some closer than others -- so the usefulness of a watchlist to me cannot be overstated. Without my watchlist, I'd be unable to keep up on my favorite sectors and what's really moving the market. Even worse, without my watchlist, I'd be lost when it came time to choose what stock I'm buying or shorting next.
What I intend to do as an experiment is to make every Wednesday "Watchlist Wednesday," where I'll discuss three companies that have crossed my radar in the past week and at what point I may consider taking action on these calls with my own money. Keep in mind these aren't concrete buy or sell recommendations, nor do I guarantee I'll take action on the companies being discussed weekly. What I can promise is that you can follow my real-life transactions through my profile, and that I, like everyone else here at The Motley Fool, will continue to hold the integrity of our disclosure policy in the highest regard.
Let me be the first to point out that I was dead, dead wrong on Pharmasset
Personally, I think Gilead is out of its gourd. Paying $11 billion for an experimental drug that isn't even out of phase 2 clinical trials is an absurd gamble in my book. Gilead could easily have had Pharmasset for less than it paid, and it also sends a message that it wasn't confident in its own line of hepatitis C hopefuls. The entire hep-C sector is looking frothy if you ask me, and Gilead puts may soon be on order for my personal portfolio.
Make no mistake about it, Chico's didn't have a particularly strong quarter based on the results reported yesterday. But investors would be foolish (with a small "f") to write Chico's off as a lost cause among clothing retailers.
Same-store sales rose 3.7% for the third quarter despite higher discounting at its flagship Chico's stores. Whereas competitors Coldwater Creek and Talbots
I really don't understand how you can go wrong over the long term by buying into one of the world's largest generic-drug producers. Next to death and taxes, the only other guarantee I can offer is that all drug patents will eventually expire, leaving Teva with a seemingly endless stream of potential generics to produce.
What makes even less sense to me is how Teva's forward earnings multiple of seven is lower than many larger pharmaceutical companies that have upward of 25%-50% of their revenue stream at risk due to patent expirations in the next few years. Teva is a cash flow machine and its dividend is just warming up, mark my words. At some point I plan to make Teva a core holding in my portfolio.
Is my bullishness or bearishness misplaced? Share your thoughts in the comments section below and consider taking my cue by adding these three companies to your free and personalized watchlist to keep up on the latest news with each company.
Fool contributor Sean Williams has no material interest in any companies mentioned in this article. He's a total nerd when it comes to making lists. You can follow him on CAPS under the screen name TMFUltraLong , track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.
The Motley Fool owns shares of Teva Pharmaceutical. Motley Fool newsletter services have recommended buying shares of Gilead Sciences, Teva Pharmaceutical, and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy that believes transparency comes first.